Lung infections in cystic fibrosis: Deriving clinical insight from microbial complexity

Expert Review of Molecular Diagnostics

Volumn 10, Issue 2, 2010, Pages 187-196

  Rogers, Geraint B ^a   Stressmann, Franziska A ^a   Walker, Alan W ^b   Carroll, Mary P ^c   Bruce, Kenneth D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bacterial community; Cystic fibrosis; Lung infections; Molecular diagnostics; Propidium monoazide

Indexed keywords

ANTIBIOTIC THERAPY; BACTERIAL CELL; BACTERIAL INFECTION; BACTERIAL VIABILITY; BACTERIUM CULTURE; COMMUNITY DYNAMICS; COMORBIDITY; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; LUNG INFECTION; MEDICAL TECHNOLOGY; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; NONHUMAN; PATHOGENICITY; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIA; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES;

EID: 77949478586     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.81     Document Type: Review

References (133)

1. WHO. World Health Report 2004. WHO, Geneva, Switzerland (2004).
2. Office of Population Censuses and Surveys. Morbidity Statistics Fom General Practice: 4th National Study. (Series MB5,3). Office for National Statistics, Newport, UK (1995).
3. McCaig LF, Ly N. National Hospital Ambulatory Medical Care Survey: 2000 emergency department summary. Adv. Data 326, 1-32 (2000).
4. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1996. Vital Health Stat. 13(134), 1-45 (1998).
5. Volturo GA, Low DE, Aghababian R. Managing acute lower respiratory tract infections in an era of antibacterial resistance. Am. J. Emerg. Med. 24(3), 329-342 (2006).
6. National Heart, Lung and Blood Institute. Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda (Md)7. US Department of Health and Human Services, Washington, DC, USA (2002).
7. Fedson DS. Was bacterial pneumonia the predominant cause of death in the 1918-1919 influenza pandemic? J. Infect. Dis. 199(9), 1408-1410 (2009).
8. Ratjen F, Doring G. Cystic fibrosis. Lancet 361(9358), 681-689 (2003).
9. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154(5), 1229-1256 (1996).
10. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. Prevention. Thorax 62(8), 723-732 (2007).
11. Investigation of Bronchoalveolar Lavage, Sputum and Associated Specimens. BSOP 57. Centre for Infections, London, UK (2008).
12. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J. Cyst. Fibros 4(Suppl. 2), 49-54 (2005).
13. Antibiotic Treatment for Cystic Fibrosis: Report of the UK Cystic Fibrosis Trust Antibiotic Group (2nd edition). UK Cystic Fibrosis Trust Antibiotic Group, Kent, UK (2002).
14. Lee T. Eradication of early pseudomonas infection in cystic fibrosis. Chron. Respir. Dis. 6(2), 99-107 (2009).
15. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3. Management. Thorax 63(2), 180-184 (2008).
16. Mattie H. Antibiotic efficacy in vivo predicted by in vitro activity. Int. J. Antimicrob. Agents 14(2), 91-98 (2000).
17. Hoiby N, Krogh Johansen H, Moser C et al. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3(1), 23-35 (2001).
18. Oliver JD. The viable but nonculturable state in bacteria. J. Microbiol. 43, 93-100 (2005).
19. Lemke MJ, Leff LG. Culturability of stream bacteria assessed at the assemblage and population levels. Microb. Ecol. 51(3), 365-374 (2006).
20. Suau A, Bonnet R, Sutren M et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl. Environ. Microbiol. 65(11), 4799-4807 (1999).
21. Socranksy SS, Gibbons RJ, Dale AC et al. The microbiota of the gingival crevice area of man. I. Total microscopic and viable counts and counts of specific organisms. Arch. Oral Biol. 8, 275-280 (1963).
22. Rogers GB, Daniels TT, Tuck A et al. Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. BMC Pulm. Med. 9(1), 14 (2009).
23. Williamson J, Marmion BP, Worswick DA et al. Laboratory diagnosis of Mycoplasma pneumoniae infection. 4. Antigen capture and PCR-gene amplification for detection of the mycoplasma: problems of clinical correlation. Epidemiol. Infect. 109(3), 519-537 (1992).
24. Greisen K, Loeffelholz M, Purohit A, Leong D. PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. J. Clin. Microbiol. 32(2), 335-351 (1994).
25. Xu J, Moore JE, Murphy PG, Millar BC, Elborn JS. Early detection of Pseudomonas aeruginosa - comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF). Ann. Clin. Microbiol. Antimicrob. 3, 21 (2004).
26. Spilker T, Coenye T, Vandamme P, LiPuma JJ. PCR-based assay for differentiation of Pseudomonas aeruginosa from other Pseudomonas species recovered from cystic fibrosis patients. J. Clin. Microbiol. 42(5), 2074-2079 (2004).
27. da Silva Filho LV, Tateno AF, Velloso Lde F et al. Identification of Pseudomonas aeruginosa, Burkholderia cepacia complex, and Stenotrophomonas maltophilia in respiratory samples from cystic fibrosis patients using multiplex PCR. Pediatr. Pulmonol. 37(6), 537-547 (2004).
28. Benson R, Tondella ML, Bhatnagar J et al. Development and evaluation of a novel multiplex PCR technology for molecular differential detection of bacterial respiratory disease pathogens. J. Clin. Microbiol. 46(6), 2074-2077 (2008).
29. Liu YT. A technological update of molecular diagnostics for infectious diseases. Infect. Disord. Drug Targets 8(3), 183-188 (2008).
30. Muldrew KL. Molecular diagnostics of infectious diseases. Curr. Opin. Pediatr. 21(1), 102-111 (2009).
31. Chan YR, Morris A. Molecular diagnostic methods in pneumonia. Curr. Opin. Infect. Dis. 20(2), 157-164 (2007).
32. Smith CJ, Osborn AM. Advantages and limitations of quantitative PCR (Q-PCR)- based approaches in microbial ecology. FEMS Microbiol. Ecol. 67(1), 6-20 (2009).
33. Kubista M, Andrade JM, Bengtsson M et al. The real-time polymerase chain reaction. Mol. Aspects Med. 27(2-3), 95-125 (2006).
34. Brittain-Long R, Nord S, Olofsson S et al. Multiplex real-time PCR for detection of respiratory tract infections. J. Clin. Virol. 41(1), 53-56 (2008).
35. Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int. J. Antimicrob. Agents 30(Suppl. 1), S7-S15 (2007).
36. Rogers GB, Carroll MP, Serisier DJ et al. Bacterial activity in cystic fibrosis lung infections. Respir. Res. 6, 49 (2005).
37. Farrelly V, Rainey FA, Stackebrandt E. Effect of genome size and rrn gene copy number on PCR amplification of 16S rRNA genes from a mixture of bacterial species. Appl. Environ. Microbiol. 61(7), 2798-2801 (1995).
38. Holland NT, Smith MT, Eskenazi B, Bastaki M. Biological sample collection and processing for molecular epidemiological studies. Mutat. Res. 543(3), 217-234 (2003).
39. De Paoli P. Bio-banking in microbiology: from sample collection to epidemiology, diagnosis and research. FEMS Microbiol. Rev. 29(5), 897-910 (2005).
40. Nocker A, Sossa KE, Camper AK. Molecular monitoring of disinfection efficacy using propidium monoazide in combination with quantitative PCR. J. Microbiol. Methods 70(2), 252-260 (2007).
41. Rogers GB, Stressmann FA, Koller G et al. Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections. Diagn. Microbiol. Infect. Dis. 62(2), 133-141 (2008).
42. Lipsett PA. Can we take the teeth out of ventilator-associated pneumonia? Crit. Care Med. 33(8), 1867-1868 (2005).
43. Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl. Environ. Microbiol. 63(11), 4516-4522 (1997).
44. Marsh TL. Terminal restriction fragment length polymorphism (T-RFLP): an emerging method for characterizing diversity among homologous populations of amplification products. Curr. Opin. Microbiol. 2(3), 323-327 (1999).
45. Dunbar J, Ticknor LO, Kuske CR. Assessment of microbial diversity in four southwestern united states soils by 16S rRNA gene terminal restriction fragment analysis. Appl. Environ. Microbiol. 66(7), 2943-2950 (2000).
46. Liesack W, Stackebrandt E. Occurrence of novel groups of the domain bacteria as revealed by analysis of genetic material isolated from an Australian terrestrial environment. J. Bacteriol. 174(15), 5072-5078 (1992).
47. Stackebrandt E, Liesack W, Goebel BM. Bacterial diversity in a soil sample from a subtropical Australian environment as determined by 16S rDNA analysis. FASEB J. 7(1), 232-236 (1993).
48. Fuhrman JA, McCallum K, Davis AA. Phylogenetic diversity of subsurface marine microbial communities from the Atlantic and Pacific oceans. Appl. Environ. Microbiol. 59(5), 1294-1302 (1993).
49. Liu SY, Zheng Z, Zhang R, Bollag JM. Sorption and metabolism of metolachlor by a bacterial community. Appl. Environ. Microbiol. 55(3), 733-740 (1989).
50. Ovreas L, Torsvik VV. Microbial diversity and community structure in two different agricultural soil communities. Microb. Ecol. 36(3), 303-315 (1998).
51. Liesack W, Schnell S, Revsbech NP. Microbiology of flooded rice paddies. FEMS Microbiol. Rev. 24(5), 625-645 (2000).
52. Rogers GB, Carroll MP, Serisier DJ et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 42(11), 5176-5183 (2004).
53. Bittar F, Richet H, Dubus JC et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 3(8), E2908 (2008).
54. Sibley CD, Parkins MD, Rabin HR et al. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 105(39), 15070-15075 (2008).
55. Ecker DJ, Sampath R, Massire C et al. Ibis T5000, a universal biosensor approach for microbiology. Nat. Rev. Microbiol. 6(7), 553-558 (2008).
56. Zaninetti-Schaerer A, Van Delden C, Genevay S, Gabay C. Total hip prosthetic joint infection due to Veillonella species. Joint Bone Spine 71(2), 161-163 (2004).
57. Kutlu SS, Sacar S, Cevahir N, Turgut H. Community-acquired Streptococcus mitis meningitis, a case report. Int. J. Infect. Dis. 12(6), E107-E109 (2008).
58. Tunney MM, Field TR, Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177(9), 995-1001 (2008).
59. Siqueira JF Jr, Rocas IN. Community as the unit of pathogenicity: an emerging concept as to the microbial pathogenesis of apical periodontitis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 107(6), 870-878 (2009).
60. Grenier D, Mayrand D. Nutritional relationships between oral bacteria. Infect. Immun. 53(3), 616-620 (1986).
61. Kolenbrander PE, Andersen RN. Intergeneric rosettes, sequestered surface recognition among human periodontal bacteria. Appl. Environ. Microbiol. 54(4), 1046-1050 (1988).
62. Siqueira JF Jr, Rocas IN, Rosado AS. Investigation of bacterial communities associated with asymptomatic and symptomatic endodontic infections by denaturing gradient gel electrophoresis fingerprinting approach. Oral Microbiol. Immunol. 19(6), 363-370 (2004).
63. Handfield M, Baker HV, Lamont RJ. Beyond good and evil in the oral cavity, insights into host-microbe relationships derived from transcriptional profiling of gingival cells. J. Dent. Res. 87(3), 203-223 (2008).
64. Kuramitsu HK, He X, Lux R, Anderson MH, Shi W. Interspecies interactions within oral microbial communities. Microbiol. Mol. Biol. Rev. 71(4), 653-670 (2007).
65. Rogers GB, Carroll MP, Bruce KD. Studying bacterial infections through culture independent approaches. J. Med. Microbiol. 58(Pt 11), 1401-1418.
66. Amadori A, Antonelli A, Balteri I et al. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir. Med. 103(3), 407-413 (2008).
67. Balfour-Lynn IA, Elborn JS. Respiratory disease, infection. In: Cystic Fibrosis. Hodson M, Geddes D, Bush A (Eds). Hodder Arnold, London, UK, 137-158 (2007).
68. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1, epidemiology and pathogenesis. Thorax 62(4), 360-367 (2007).
69. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. USA 103(22), 8487-8492 (2006).
70. Hollsing AE, Granstrom M, Vasil ML, Wretlind B, Strandvik B. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J. Clin. Microbiol. 25(10), 1868-1874 (1987).
71. Costerton JW. The Biofilm Primer. Springer-Verlag, Berlin, Germany (2007).
72. Sibley CD, Duan K, Fischer C et al. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog. 4(10), E1000184 (2008).
73. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 141(4 Pt 1), 914-921 (1990).
74. Smith AL, Redding G, Doershuk C et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J. Pediatr. 112(4), 547-554 (1988).
75. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis inhaled tobramycin study group. N. Engl. J. Med. 340(1), 23-30 (1999).
76. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 55(1), 10-21 (2005).
77. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials, a class of potent immunomodulators. Int. J. Antimicrob. Agents 31(1), 12-20 (2008).
78. Bjarnsholt T, Kirketerp-Moller K, Jensen PO et al. Why chronic wounds will not heal, a novel hypothesis. Wound Repair Regen. 16(1), 2-10 (2008).
79. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109(3), 317-325 (2002).
80. Bjarnsholt T, Jensen, PO, Fiandaca MJ et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44, 547-558 (2009).
81. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir. Care 54, 628-640 (2009).
82. Kobayashi H. Airway biofilms, implications for pathogenesis and therapy of respiratory tract infections. Treat Respir. Med. 4(4), 241-253 (2005).
83. Tre-Hardy M, Mace C, El Manssouri N et al. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates, the importance of the biofilm model. Int. J. Antimicrob. Agents 33(1), 40-45 (2009).
84. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63(3), 485-488 (2009).
85. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42(5), 1915-1922 (2004).
86. Wu CL, Domenico P, Hassett DJ et al. Subinhibitory bismuth-thiols reduce virulence of Pseudomonas aeruginosa. Am. J. Respir. Cell. Mol. Biol. 26(6), 731-738 (2002).
87. Devriese LA, Dutta GN. Antibiotic sensitivity testing: correlations between in vitro tests in vivo situations. Ann. Rech. Vet. 12, 41-46 (1981).
88. Nagano Y, Millar BC, Goldsmith CE et al. Emergence of Scedosporium apiospermum in patients with cystic fibrosis. Arch. Dis. Child 92(7), 607 (2007).
89. Bouchara JP, Hsieh HY, Croquefer S et al. Development of an oligonucleotide array for direct detection of fungi in sputum samples from patients with cystic fibrosis. J. Clin. Microbiol. 47(1), 142-152 (2009).
90. Kennedy N, Brodie E, Connolly J, Clipson N. Seasonal influences on fungal community structure in unimproved and improved upland grassland soils. Can. J. Microbiol. 52(7), 689-694 (2006).
91. Anderson IC, Cairney JW. Diversity and ecology of soil fungal communities. Increased understanding through the application of molecular techniques. Environ. Microbiol. 6(8), 769-779 (2004).
92. Hansgate AM, Schloss PD, Hay AG, Walker LP. Molecular characterization of fungal community dynamics in the initial stages of composting. FEMS Microbiol. Ecol. 51(2), 209-214 (2005).
93. Woo S, Fogliano V, Scala F, Lorito M. Synergism between fungal enzymes and bacterial antibiotics may enhance biocontrol. Antonie Van Leeuwenhoek 81(1-4), 353-356 (2002).
94. Rousk J, Demoling LA, Bahr A, Baath E. Examining the fungal and bacterial niche overlap using selective inhibitors in soil. FEMS Microbiol. Ecol. 63(3), 350-358 (2008).
95. Romano JD, Kolter R. Pseudomonas- saccharomyces interactions. Influence of fungal metabolism on bacterial physiology and survival. J. Bacteriol. 187(3), 940-948 (2005).
96. Pribble CG, Black PG, Bosso JA, Turner RB. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J. Pediatr. 117(2 Pt 1), 200-204 (1990).
97. Ong EL, Ellis ME, Webb AK et al. Infective respiratory exacerbations in young adults with cystic fibrosis, role of viruses and atypical microorganisms. Thorax 44(9), 739-742 (1989).
98. Armstrong D, Grimwood K, Carlin JB et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr. Pulmonol. 26(6), 371-379 (1998).
99. Collinson J, Nicholson KG, Cancio E et al. Effects of upper respiratory tract infections in patients with cystic fibrosis. Thorax 51(11), 1115-1122 (1996).
100. Ramsey BW, Gore EJ, Smith AL et al. The effect of respiratory viral infections on patients with cystic fibrosis. Am. J. Dis. Child 143(6), 662-668 (1989).
101. Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N. Engl. J. Med. 311(26), 1653-1658 (1984).
102. Olesen HV, Nielsen LP, Schiotz PO. Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr. Pulmonol. 41(12), 1197-1204 (2006).
103. Hament JM, Kimpen JL, Fleer A, Wolfs TF. Respiratory viral infection predisposing for bacterial disease, a concise review. FEMS Immunol. Med. Microbiol. 26(3-4), 189-195 (1999).
104. Van Ewijk BE, Wolfs TF, Aerts PC et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr. Res. 61(4), 398-403 (2007).
105. Petersen NT, Hoiby N, Mordhorst CH et al. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. Acta Paediatr. Scand. 70(5), 623-628 (1981).
106. Wat D, Gelder C, Hibbitts S et al. The role of respiratory viruses in cystic fibrosis. J. Cyst. Fibros. 7(4), 320-328 (2008).
107. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch. Dis. Child 73(2), 117-120 (1995).
108. Punch G, Syrmis MW, Rose BR et al. Method for detection of respiratory viruses in the sputa of patients with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 24(1), 54-57 (2005).
109. Kim SR, Ki CS, Lee NY. Rapid detection and identification of 12 respiratory viruses using a dual priming oligonucleotide system-based multiplex PCR assay. J. Virol. Methods 156(1-2), 111-116 (2009).
110. Murali S, Langston AA, Nolte FS et al. Detection of respiratory viruses with a multiplex polymerase chain reaction assay (MultiCode-PLx respiratory virus panel) in patients with hematologic malignancies. Leuk. Lymphoma 50(4), 619-624 (2009).
111. Terlizzi ME, Massimiliano B, Francesca S et al. Quantitative RT real time PCR and indirect immunofluorescence for the detection of human parainfluenza virus 1, 2, 3. J. Virol. Methods 160(1-2), 172-177 (2009).
112. Rolain JM, Francois P, Hernandez D et al. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol. Direct 4, 1 (2009).
113. Pal C, Macia MD, Oliver A, Schachar I, Buckling A. Coevolution with viruses drives the evolution of bacterial mutation rates. Nature 450(7172), 1079-1081 (2007).
114. Poullain V, Gandon S, Brockhurst MA, Buckling A, Hochberg ME. The evolution of specificity in evolving and coevolving antagonistic interactions between a bacteria and its phage. Evolution 62(1), 1-11 (2008).
115. Brockhurst MA, Buckling A, Rainey PB. The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa. Proc. Biol. Sci. 272(1570), 1385-1391 (2005).
116. Rice SA, Tan CH, Mikkelsen PJ et al. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J. 3(3), 271-282 (2009).
117. Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack. The role of phage-borne polysaccharide depolymerase. Microbiology 144(Pt 11), 3039-3047 (1998).
118. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. USA 104(27), 11197-11202 (2007).
119. Zegans ME, Wagner JC, Cady KC et al. Interaction between bacteriophage DMS3 and host CRISPR region inhibits group behaviors of Pseudomonas aeruginosa. J. Bacteriol. 191(1), 210-219 (2009).
120. Casadevall A, Pirofski LA. Microbial virulence results from the interaction between host and microorganism. Trends Microbiol. 11(4), 157-158; author reply 158-159 (2003).
121. Krober M, Bekel T, Diaz NN et al. Phylogenetic characterization of a biogas plant microbial community integrating clone library 16S-rDNA sequences and metagenome sequence data obtained by 454-pyrosequencing. J. Biotechnol. 142(1), 38-49 (2009).
122. Lauber CL, Hamady M, Knight R, Fierer N. Soil pH as a predictor of soil bacterial community structure at the continental scale, a pyrosequencing-based assessment. Appl. Environ. Microbiol. 75(15), 5111-5120 (2009).
123. Armougom F, Bittar F, Stremler N et al. Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. Eur. J. Clin. Microbiol. Infect. Dis. 28(9), 1151-1154 (2009).
124. Tringe SG, Hugenholtz P. A renaissance for the pioneering 16S rRNA gene. Curr. Opin. Microbiol. 11, 442-446 (2008).
125. Quince C, Lanzén A, Curtis TP et al. Accurate determination of microbial diversity from 454 pyrosequencing data. Nat. Methods 6(9), 639-641 (2009).
126. Gomez-Alvarez V, Teal TK, Schmidt TM. Systematic artifacts in metagenomes from complex microbial communities. ISME J. 3(11), 1314-1317 (2009).
127. Huse SM, Dethlefsen L, Huber JA et al. Exploring microbial diversity and taxonomy using SSU rRNA hypervariable tag sequencing. PLOS Genet. 4(11), E1000255 (2008).
128. White JR, Nagarajan N, Pop M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput. Biol. 5(4), E1000352 (2009).
129. Sun Y, Cai Y, Liu L et al. ESPRIT: estimating species richness using large collections of 16S rRNA pyrosequences. Nucleic Acids Res. 37(10), E76 (2009).
130. Hamady M, Lozupone C, Knight R. Fast UniFrac: facilitating high-throughput phylogenetic analyses of microbial communities including analysis of pyrosequencing and PhyloChip data. ISME J. 4(1), 17-27 (2009).
131. Brady A, Salzberg SL, Phymm BL. Metagenomic phylogenetic classification with interpolated Markov models. Nat. Methods 6(9), 673-676 (2009).
132. Schloss PD, Westcott SL, Ryabin T et al. Introducing mothur: open source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75(23), 7537-7541 (2009).
133. Brodie EL, DeSantis TZ, Joyner DC et al. Application of a high-density oligonucleotide microarray approach to study bacterial population dynamics during uranium reduction and reoxidation. Appl. Environ. Microbiol. 72, 6288-6298 (2006).